Nelson Gruszczynski
Papers
2
Total Citations
145
H-Index
2
About
Nelson Gruszczynski is a pioneering translational researcher specializing in personalized oncology, rare cancers, and functional drug screening platforms. His major contributions lie in developing innovative, patient-specific approaches to identify effective treatments for individuals with difficult-to-treat malignancies. In his landmark 2019 study, Gruszczynski and colleagues created a personalized platform using a robotics-based screen in Drosophila, which identified the combination of trametinib plus zoledronate as a candidate therapy for a patient with KRAS-mutant metastatic colorectal cancer. This treatment led to a strong partial response with stability lasting 11 months—a remarkable outcome for a notoriously aggressive cancer. The paper has garnered 107 citations, reflecting its significant impact on the field of precision oncology. In 2021, he extended this approach to adenoid cystic carcinoma (ACC), a rare salivary gland cancer with limited treatment options, demonstrating the platform’s versatility in identifying novel, personalized therapies. This work, cited 38 times, highlights his commitment to addressing unmet needs in rare diseases. Gruszczynski’s research bridges functional genomics and clinical application, offering hope for patients with otherwise refractory cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2